Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Shorter radiation may ease lung cancer treatment burden

NCT ID NCT06483308

Symptom relief Sponsor: University Hospitals Coventry and Warwickshire NHS Trust Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a shorter course of high-dose radiation for people with stage IV lung cancer. The goal was to see if giving fewer, larger doses over fewer days could be as safe and effective as the standard longer schedule. 37 participants received radiation every other day for a total of 6 sessions, and researchers tracked side effects like throat pain and quality of life.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 37 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2024

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 * Patient has locally advanced (stage IIIB or IIIC) or metastatic (stage IV) NSCLC * Patient is treatment naïve or had limited progression after first-line systemic therapy (using chemotherapy, immunotherapy, or targeted therapy) * Patient is suitable for high dose palliative RT (36Gy in 12# or 39Gy in 13#) * Obtained written informed consent for the SHiP-Rt study. * Patients receiving RT after first-line systemic therapy must have a wash-out period of at least 3 weeks (i.e., 3-4 weeks). * Treatment naïve patients should be able to proceed to definitive systemic therapy without undue delay, i.e., within 3-4 weeks. Exclusion Criteria: * Contraindication for thoracic RT * Requiring lung RT after second-line systemic therapy for NSCLC * Has more than 1 cancer that is requiring active treatment * On cytotoxic treatment for rheumatoid arthritis or connective tissue disorders * Poor life expectancy, likely less than 6 months * Patients with difficulty regarding compliance to the study treatment or follow-up * Previous radiotherapy to the same area

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Non-small cell lung cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

lung cancer lung neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Stage IV lung cancer

Contacts and locations

Locations

  • The Shrewsbury and Telford Hospital NHS Trust

    Shrewsbury, West Midlands, SY2 6LG, United Kingdom

  • University Hospitals Birmingham NHS Foundation Trust

    Birmingham, West Midlands, B15 2, United Kingdom

  • University Hospitals Coventry and Warwickshire

    Coventry, Warwickshire, CV2 2DX, United Kingdom

  • University Hospitals of North Midlands NHS Trust

    Stoke-on-Trent, Staffordshire, ST4 6QG, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.